Govt panel recommends allowing Biological E Corbevax as booster for Covishield, Covaxin recipients

India's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 Immunisation programme.;

Published On 2022-08-03 09:00 GMT | Update On 2024-02-15 14:21 GMT

New Delhi: A government panel on Covid immunisation has recommended allowing Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin, official sources said on Tuesday.

If approved by the government, this would be the first time a booster dose of a Covid vaccine different from the one used for primary vaccination would be allowed in the country.

The COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) made the recommendation in its 48th meeting held on July 20, an official source told PTI.

"Corbevax may be considered for a third/precaution dose six months after completion of primary series of Covaxin or Covishield vaccines for population above 18 years wherever indicated," the recommendation stated.

India's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 Immunisation programme.

The COVID-19 Working Group (CWG), in its July 20 meeting, reviewed data of the double-blind randomized phase-3 clinical study which evaluated the immunogenicity and safety of booster dose of Corbevax vaccine when administered to COVID-19-negative adult volunteers of age 18-80 years previously vaccinated with two doses of either Covishield or Covaxin.

"Following the examination of the data, the CWG observed that Corbevax vaccine can induce significant increase in antibody titers when given to those who have received either Covaxin or Covishield, which is likely to be protective as per the neutralization data also," the source said.

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above.

At present, the same COVID-19 vaccine which has been used for administration of first and second doses is being given as precaution dose to all aged 18 years and above.

More than 4.13 crore precaution doses have been administered in the 18-59 age group while over 5.11 crore precaution doses have been given to those aged 60 and above and heathcare and frontline workers.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.

The country began inoculating children aged 12-14 from March 16 and also removed the comorbidity clause making all people aged above 60 eligible for the precaution dose of Covid vaccine.

India on April 10 began administering precaution doses of COVID-19 vaccines to all aged above 18 years.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Govt panel recommends allowing Biological E Corbevax as booster for Covishield, Covaxin recipients

India's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 Immunisation programme.;

Similar News

One-shot Dengue vaccine 'DengiAll' completes 70% enrolment of participants in Phase III trial: Centre

Sun Pharma Gets Relief As Delhi HC Bars Use of BERIVITAL, BEZOLIC, DOZE-30 For Trademark Infringement

Senores Pharma appoints Sanjay Moralwar as Head of IT

CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver, Mandates Phase-IV Trial in India

SIL declares profit from operations growth as +6% vs previous year

Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial Proposal

Health Ministry Notifies Cosmetics Rules 2025, Empowers States To Suspend Licences

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray